|
1
|
Faderl S, Kantarjian HM and Talpaz M:
Chronic myelogenous leukemia: update on biology and treatment.
Oncology (Williston Park). 13:169–180; discussion 181, 184.
1999.
|
|
2
|
Ben-Neriah Y, Daley GQ, Mes-Masson AM,
Witte ON and Baltimore D: The chronic myelogenous leukemia-specific
p210 protein is the product of the bcr/abl hybrid gene. Science.
233:212–214. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ren R: Mechanisms of BCR-ABL in the
pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer.
5:172–183. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Druker BJ, Guilhot F, O'Brien SG, Gathmann
I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM,
Stone RM, et al: Five-year follow-up of patients receiving imatinib
for chronic myeloid leukemia. N Engl J Med. 355:2408–2417. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Santos FP, Kantarjian H, Quintas-Cardama A
and Cortes J: Evolution of therapies for chronic myelogenous
leukemia. Cancer J. 17:465–476. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zabriskie MS, Eide CA, Tantravahi SK,
Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva
M, Cortes JE, et al: BCR-ABL1 compound mutations combining key
kinase domain positions confer clinical resistance to ponatinib in
Ph chromosome-positive leukemia. Cancer Cell. 26:428–442. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shah NP, Nicoll JM, Nagar B, Gorre ME,
Paquette RL, Kuriyan J and Sawyers CL: Multiple BCR-ABL kinase
domain mutations confer polyclonal resistance to the tyrosine
kinase inhibitor imatinib (STI571) in chronic phase and blast
crisis chronic myeloid leukemia. Cancer Cell. 2:117–125. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Apperley JF: Part I: Mechanisms of
resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol.
8:1018–1029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Talpaz M, Shah NP, Kantarjian H, Donato N,
Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E,
et al: Dasatinib in imatinib-resistant Philadelphia
chromosome-positive leukemias. N Engl J Med. 354:2531–2541. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O'Hare T, Shakespeare WC, Zhu X, Eide CA,
Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al:
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia,
potently inhibits the T315I mutant and overcomes mutation-based
resistance. Cancer Cell. 16:401–412. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Poch Martell M, Sibai H, Deotare U and
Lipton JH: Ponatinib in the therapy of chronic myeloid leukemia.
Expert Rev Hematol. 9:923–932. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Talpaz M, Kantarjian H, Kurzrock R,
Trujillo JM and Gutterman JU: Interferon-alpha produces sustained
cytogenetic responses in chronic myelogenous leukemia. Philadelphia
chromosome-positive patients. Ann Intern Med. 114:532–538. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
El Eit R, Itani AR, Nassar F, Rasbieh N,
Jabbour M, Santina A, Zaatari G, Mahon FX, Bazarbachi A and Nasr R:
Antitumor efficacy of arsenic/interferon in preclinical models of
chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Cancer. 125:2818–2828. 2019.PubMed/NCBI
|
|
14
|
Zhou X, Michal JJ, Zhang L, Ding B, Lunney
JK, Liu B and Jiang Z: Interferon induced IFIT family genes in host
antiviral defense. Int J Biol Sci. 9:200–208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stawowczyk M, Van Scoy S, Kumar KP and
Reich NC: The interferon stimulated gene 54 promotes apoptosis. J
Biol Chem. 286:7257–7266. 2011. View Article : Google Scholar :
|
|
16
|
Chen L, Liu S, Xu F, Kong Y, Wan L, Zhang
Y and Zhang Z: Inhibition of proteasome activity induces
aggregation of IFIT2 in the centrosome and enhances IFIT2-induced
cell apoptosis. Int J Biol Sci. 13:383–390. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vardiman JW, Harris NL and Brunning RD:
The world health organization (WHo) classification of the myeloid
neoplasms. Blood. 100:2292–2302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu S, Wan J, Kong Y, Zhang Y, Wan L and
Zhang Z: Inhibition of CRL-NEDD8 pathway as a new approach to
enhance ATRA-induced differentiation of acute promyelocytic
leukemia cells. Int J Med Sci. 15:674–681. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Tomoda K, Kato JY, Tatsumi E, Takahashi T,
Matsuo Y and Yoneda-Kato N: The Jab1/COP9 signalosome subcomplex is
a downstream mediator of Bcr-Abl kinase activity and facilitates
cell-cycle progression. Blood. 105:775–783. 2005. View Article : Google Scholar
|
|
21
|
Morimoto M, Nishida T, Honda R and Yasuda
H: Modification of cullin-1 by ubiquitin-like protein Nedd8
enhances the activity of SCF(skp2) toward p27(kip1). Biochem
Biophys Res Commun. 270:1093–1096. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen L, Zhai W, Zheng X, Xie Q, Zhou Q,
Tao M, Zhu Y, WU C and Jiang J: Decreased IFIT2 expression promotes
gastric cancer progression and predicts poor prognosis of the
patients. Cell Physiol Biochem. 45:15–25. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen H, Zhan M, Zhang Y, Huang S, Xu S,
Huang X, He M, Yao Y, Man M and Wang J: PLZF inhibits proliferation
and metastasis of gallbladder cancer by regulating IFIT2. Cell
Death Dis. 9:712018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ohsugi T, Yamaguchi K, Zhu C, Ikenoue T
and Furukawa Y: Decreased expression of interferon-induced protein
2 (IFIT2) by Wnt/β-catenin signaling confers anti-apoptotic
properties to colorectal cancer cells. Oncotarget. 8:100176–100186.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Kong Y, Liu S, Zeng L, Wan L and
Zhang Z: Curcumin induces apoptosis in human leukemic cell lines
through an IFIT2-dependent pathway. Cancer Biol Ther. 18:43–50.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang R, Liu H, Chen Y, He Y, Kang Q, Tu
S, He Y, Zhou X, Wang L, yang J, et al: EPS8 regulates
proliferation, apoptosis and chemosensitivity in BCR-ABL positive
cells via the BCR-ABL/PI3K/AKT/mTOR pathway. Oncol Rep. 39:119–128.
2018.
|
|
27
|
Toyoshima H and Hunter T: p27, a novel
inhibitor of g1 cyclin-Cdk protein kinase activity, is related to
p21. Cell. 78:67–74. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen
Y, Sullivan C, Cerny J, Hutchinson L, Higgins A, et al: The Blk
pathway functions as a tumor suppressor in chronic myeloid leukemia
stem cells. Nat Genet. 44:861–871. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakao T, Geddis AE, Fox NE and Kaushansky
K: PI3K/Akt/ FOXO3a pathway contributes to thrombopoietin-induced
proliferation of primary megakaryocytes in vitro and in vivo via
modulation of p27(Kip1). Cell Cycle. 7:257–266. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shin I, Yakes FM, Rojo F, Shin NY, Bakin
AV, Baselga J and Arteaga CL: PKB/Akt mediates cell-cycle
progression by phosphorylation of p27(Kip1) at threonine 157 and
modulation of its cellular localization. Nat Med. 8:1145–1152.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wisdom R, Johnson RS and Moore C: c-Jun
regulates cell cycle progression and apoptosis by distinct
mechanisms. EMBO J. 18:188–197. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Khattar E and Kumar V: Mitogenic
regulation of p27(Kip1) gene is mediated by AP-1 transcription
factors. J Biol Chem. 285:4554–4561. 2010. View Article : Google Scholar
|
